Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synthroid 300 μg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Levothyroxine Sodium Tablets 300 μg |
| 2 | ACTIVE_COMPARATOR | Synthroid® Tablets 300 μg |
| Name | Type | Description |
|---|---|---|
| Levothyroxine Sodium Tablets 300 μg | DRUG | 2x300mcg, single dose fasting |
| Synthroid® Tablets 300 μg | DRUG | 2x300mcg, single dose fasting |
Inclusion Criteria: 1. Age: 18-50 years. 2. Sex: Men and/or non-pregnant, non-lactating women. 1. Women of childbearing potential must have negative serum β human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to each dose ad...
Synthroid 300 μg is a small molecule drug being developed by Viatris Inc. for use in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial involving 30 participants. The drug is being studied as a levothyroxine sodium tablet formulation.
Synthroid 300 μg is developed by Viatris Inc., a company traded under the ticker VTRS. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers. Viatris is conducting research on this levothyroxine sodium tablet formulation.
Synthroid 300 μg is in Phase 1 clinical development. It has one completed trial with 30 participants, and no active trials are currently listed. The drug is being studied in healthy volunteers as a levothyroxine sodium tablet formulation.
Synthroid 300 μg has one completed clinical trial, NCT00647855, titled "Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg." This Phase 1 study enrolled 30 healthy volunteers in the United States and was active-controlled.
Synthroid 300 μg is an investigational drug currently in Phase 1 clinical development. It is not approved by the FDA, as it is still being studied in clinical trials. The drug has one completed trial in healthy volunteers, but no active trials are ongoing.